Most Read Articles
01 Oct 2013

Heart disease is still New Zealand’s biggest killer, with one Kiwi dying from coronary heart disease every 90 minutes. Pharmacy Today New Zealand looks at how pharmacists can help

Pearl Toh, 11 Oct 2017
Clinical practice is an art guided by good science, and clinical practice guideline (CPG) is meant to guide in integrating the art and science of clinical practice for the long-term benefits of patients, said Dr Abdul Rashid Abdul Rahman, a consultant cardiovascular physician at An-Nur Specialist Hospital in Bangi, Malaysia, during the 13th Asian-Pacific Congress of Hypertension (APCH) held in Singapore.
08 Oct 2017
Treatment with vismodegib does not appear to increase the risk of subsequent squamous cell carcinoma (SCC) in comparison with standard surgical treatment of basal cell carcinoma (BCC), a recent study suggests.
01 Sep 2017
Complementary medicines can play an important part in maintaining wellness, preventing deficiencies and optimizing health outcomes, says Dr Lesley Braun PhD, Director of the Blackmores Institute. 

TNF inhibitors may slightly increase risk of developing severe extra-articular RA

10 Jul 2017

Patients treated with tumour necrosis factor (TNF) inhibitors are marginally prone to develop severe extra-articular rheumatoid arthritis (ExRA), a study suggests. In addition, rheumatoid factor (RF)-positive patients with disabling disease of long duration are at an increased risk of developing severe ExRA.

Researchers recruited a dynamic community-based cohort of patients with RA (n=1,977) to assess whether treatment with TNF inhibitors affected the risk of developing severe ExRA manifestations, as well as to study potential predictors for developing ExRA. They reviewed clinical records and identified cases of severe ExRA. Information on exposure to TNF inhibitors was obtained from a regional register.

Analysis of exposure to TNF inhibitors was done in a time-dependent fashion. Additionally, researchers compared the incidence of severe ExRA in exposed patients with the incidence in those who were unexposed. Cox regression models were used to evaluate possible predictors of severe ExRA.

A total of 17 patients had new onset of severe ExRA during treatment with TNF inhibitors in 2,400 person-years at risk (0.71/100; 95 percent CI, 0.41 to 1.13) compared with 104 in 15,599 person-years (0.67/100; 0.54 to 0.81) in those without TNF inhibitors, corresponding to an incidence rate ratio of 1.06 (0.60 to 1.78).

Anti-TNF‒treated patients had a hazard ratio for ExRA of 1.21 (1.02 to 1.43), adjusted for age and sex; the findings were similar in models adjusted for time-dependent Health Assessment Questionnaire and propensity for anti-TNF treatment.

The predictors for ExRA were male sex, positive RF, long disease duration and greater disability, according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Oct 2013

Heart disease is still New Zealand’s biggest killer, with one Kiwi dying from coronary heart disease every 90 minutes. Pharmacy Today New Zealand looks at how pharmacists can help

Pearl Toh, 11 Oct 2017
Clinical practice is an art guided by good science, and clinical practice guideline (CPG) is meant to guide in integrating the art and science of clinical practice for the long-term benefits of patients, said Dr Abdul Rashid Abdul Rahman, a consultant cardiovascular physician at An-Nur Specialist Hospital in Bangi, Malaysia, during the 13th Asian-Pacific Congress of Hypertension (APCH) held in Singapore.
08 Oct 2017
Treatment with vismodegib does not appear to increase the risk of subsequent squamous cell carcinoma (SCC) in comparison with standard surgical treatment of basal cell carcinoma (BCC), a recent study suggests.
01 Sep 2017
Complementary medicines can play an important part in maintaining wellness, preventing deficiencies and optimizing health outcomes, says Dr Lesley Braun PhD, Director of the Blackmores Institute.